Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“Any type of irAE occurs in 80-90% of patients, with higher grade events (as categorized by the Common Terminology Criteria for Adverse Events) occurring in 15-20% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 60% of patients treated with combination of ipilimumab and nivolumab.9”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 2×
“AJCC denotes American Joint Committee on Cancer 2009 classification, 7th edition.(14) 0.”
BackgroundSelf-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citation
Cited by
Items 101–200 of 1,000
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
Wang, Y.-N., Lee, H.-H., Hsu, J. L., Yu, D., & Hung, M.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00670-x · Cited by 192
Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy
Buchwald, Z. S., Nasti, T. H., Lee, J., Eberhardt, C. S., Wieland, A., Im, S. J., Lawson, D., Curran, W., Ahmed, R., & Khan, M. K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000867 · Cited by 183
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O., Stern, M.-H., Pierga, J.-Y., & Bidard, F.-C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0074-3 · Cited by 196
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
Tan, L., Sandhu, S., Lee, R. J., Li, J., Callahan, J., Ftouni, S., Dhomen, N., Middlehurst, P., Wallace, A., Raleigh, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz048 · Cited by 186
“Eighteen (14%) patients participated on an adjuvant immune checkpoint inhibitor clinical trial [7, 9] Somatic mutation testing was performed in 126/133 individuals due to availability of primary tumor tissue and identified at least one somatic mutation in 99/126 (79%) patients.”
BackgroundSelf-citationEggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.001 · Cited by 182
Self-citationWong, P. F., Wei, W., Smithy, J. W., Acs, B., Toki, M. I., Blenman, K. R. M., Zelterman, D., Kluger, H. M., & Rimm, D. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2652 · Cited by 182
“Further investigation of this biomarker is planned, especially in the adjuvant setting where only 1 in 5 treated melanoma patients benefit from anti–PD-1 therapy (9).”
BackgroundThe Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
O'Donnell, J. S., Hoefsmit, E. P., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2641 · Cited by 182
Self-citationBiomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185
“Severe irAEs (grade ≥3) have occurred in 28–56% and 21–32% in patients treated with ipilimumab or anti-PD-1/anti-PD-L1 antibodies, respectively (10, 12, 16, 162, 163).”
BackgroundImmune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J., & Collins, D. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 182
Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01381 · Cited by 184
“Significant RFS benefits versus placebo were reported for pembrolizumab in KeyNote-054 and the combination of dabrafenib and trametinib in patients with BRAF-mutated melanoma in COMBI-AD.(7,8) The adjuvant standard of care has clearly shifted in favor of these new agents based on the magnitude of RFS benefits seen and…”
BackgroundIntratumoral Immunotherapy for Early-stage Solid Tumors
Hong, W. X., Haebe, S., Lee, A. S., Westphalen, C. B., Norton, J. A., Jiang, W., & Levy, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3642 · Cited by 183
Faje, A., Reynolds, K., Zubiri, L., Lawrence, D., Cohen, J. V., Sullivan, R. J., Nachtigall, L., & Tritos, N. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0238 · Cited by 174
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Weber, J. S., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., Pigozzo, J., Gogas, H., Dalle, S., Meyer, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00533 · Cited by 173
Self-citationLee, J. B., Kim, H. R., & Ha, S.-J. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 174
“Pembrolizumab is indicated for the treatment of melanoma, NSCLC, SCCHN, UC, MSI-H or dMMR cancer, MSI-H or dMMR colorectal cancer, GC, EC, cervical cancer, HCC, merkel cell carcinoma, RCC, endometrial carcinoma, tumor mutational burden-high cancer, cutaneous squamous cell carcinoma, and triple-negative breast cancer (…”
BackgroundInfluentialNovel Approaches to Improve the Efficacy of Immuno-Radiotherapy
Shevtsov, M., Sato, H., Multhoff, G., & Shibata, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00156 · Cited by 173
“The PD-L1 expression in tumors, as well as immune cells surrounding the tumor, can affect the efficacy of anti-PD-1/PD-L1 therapy (44, 45).”
BackgroundNaidoo, J., Murphy, C., Atkins, M. B., Brahmer, J. R., Champiat, S., Feltquate, D., Krug, L. M., Moslehi, J., Pietanza, M. C., Riemer, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006398 · Cited by 165
Self-citationLo, S. N., Ma, J., Scolyer, R. A., Haydu, L. E., Stretch, J. R., Saw, R. P. M., Nieweg, O. E., Shannon, K. F., Spillane, A. J., Ch’ng, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02362 · Cited by 168
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Meshcheryakov, A., Khattak, A., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200214 · Cited by 160
Self-citationNewell, F., Pires da Silva, I., Johansson, P. A., Menzies, A. M., Wilmott, J. S., Addala, V., Carlino, M. S., Rizos, H., Nones, K., Edwards, J. J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.11.012 · Cited by 164
Self-citationPires da Silva, I., Lo, S., Quek, C., Gonzalez, M., Carlino, M. S., Long, G. V., & Menzies, A. M. (2020) · Cancer · doi:10.1002/cncr.32522 · Cited by 163
“The Study of Pembrolizumab Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (KEYNOTE-054/EORTC-1325) currently in follow-up will clarify this issue.(21) In addition to size, the site of metastases also influences response to treatment and survival.”
BackgroundSelf-citationTargeted Therapy and Immunotherapy for Melanoma in Japan
Namikawa, K., & Yamazaki, N. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0607-8 · Cited by 159
Dummer, R., Brase, J. C., Garrett, J., Campbell, C. D., Gasal, E., Squires, M., Gusenleitner, D., Santinami, M., Atkinson, V., Mandalà, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30062-0 · Cited by 161
Self-citationThe Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Sasso, J. M., Tenchov, R., Bird, R. E., Iyer, K. A., Ralhan, K., Rodríguez, Y., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00374 · Cited by 175
Cutaneous Melanoma—A Review in Detection, Staging, and Management
Hartman, R. I., & Lin, J. Y. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.09.005 · Cited by 167
Integration of radiotherapy and immunotherapy for treatment of oligometastases
Pitroda, S. P., Chmura, S. J., & Weichselbaum, R. R. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30157-3 · Cited by 167
Long, G. V., Luke, J. J., Khattak, M. A., de la Cruz‐Merino, L., Vecchio, M. D., Rutkowski, P. L., Spagnolo, F., Mackiewicz, J., Chiarion‐Sileni, V., Kirkwood, J. M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00559-9 · Cited by 160
Self-citationWei, C., Zhu, M.-X., Zhang, P., Huang, X., Wan, J., Yao, X., Hu, Z.-T., Chai, X., Peng, R., Yang, X., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.019 · Cited by 166
Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
Gellrich, F. F., Schmitz, M., Beissert, S., & Meier, F. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010223 · Cited by 165
“In the phase III EORTC 1325 study [39], patients with completely resected locoregional metastases received anti-PD-1 pembrolizumab (514 patients) or placebo (505 patients) for 1 year.”
BackgroundFinal Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Long, G. V., Hauschild, A., Santinami, M., Kirkwood, J. M., Atkinson, V. G., Mandalà, M., Merelli, B., Chiarion‐Sileni, V., Nyakas, M., Haydon, A. M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404139 · Cited by 155
Self-citationTumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., & Milella, M. (2020) · Cancers · doi:10.3390/cancers12102870 · Cited by 170
“Although preclinical research has obtained promising results in several cancer models, including melanoma, clinical results to date have been largely unsatisfactory [75,76].”
ResultDendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
van Willigen, W. W., Bloemendal, M., Gerritsen, W. R., Schreibelt, G., de Vries, I. J. M., & Bol, K. F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02265 · Cited by 150
“In addition, both nivolumab and pembrolizumab have shown to increase PFS in the adjuvant setting for melanoma (19, 20).”
BackgroundProspects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
Versluis, J. M., Menzies, A. M., Sikorska, K., Rozeman, E. A., Saw, R. P. M., van Houdt, W. J., Eriksson, H., Klop, W. M. C., Ch’ng, S., van Thienen, J. V., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.004 · Cited by 151
Self-citationCheckpoint Inhibitor–Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes
Tsang, V. H. M., McGrath, R. T., Clifton-Bligh, R. J., Scolyer, R. A., Jakrot, V., Guminski, A. D., Long, G. V., & Menzies, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00423 · Cited by 139
Self-citationConsiderations for treatment duration in responders to immune checkpoint inhibitors
Marron, T. U., Ryan, A. E., Reddy, S. M., Kaczanowska, S., Younis, R. H., Thakkar, D., Zhang, J., Bartkowiak, T., Howard, R., Anderson, K. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001901 · Cited by 137
Tumor intrinsic and extrinsic immune functions of CD155
O’Donnell, J. S., Madore, J., Li, X.-Y., & Smyth, M. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.013 · Cited by 151
Arance, A. M., de la Cruz‐Merino, L., Petrella, T. M., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Márquez‐Rodas, I., Spreafico, A., Atkinson, V. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00221 · Cited by 144
Self-citationIncreasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 143
Cardiotoxicity from immune checkpoint inhibitors
Michel, L., Rassaf, T., & Totzeck, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100420 · Cited by 148
BRAF Gene and Melanoma: Back to the Future
Ottaviano, M., Giunta, E. F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D., Cardalesi, C., Rosanova, M., Placido, P. D., Pietroluongo, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073474 · Cited by 131
“brolizumab, for the demonstrated significant improvement in RFS in Phase 3 comparative trials, received FDA and EMA approval for the adjuvant treatment of completely resected melanoma patients [80,81].”
Background3D approaches to model the tumor microenvironment of pancreatic cancer
Tomás-Bort, E., Kieler, M., Sharma, S., Candido, J. B., & Loessner, D. (2020) · Theranostics · doi:10.7150/thno.42441 · Cited by 114
“In comparison to other malignant diseases, such as melanoma [4], lung cancer [5] and breast cancer [6], that have witnessed the implementation of targeted therapies or immunotherapies, systemic chemotherapy remains the standard treatment of metastatic pancreatic cancer.”
Surgery-mediated tumor-promoting effects on the immune microenvironment
Cheng, X., Zhang, H., Hamad, A., Huang, H., & Tsung, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.006 · Cited by 135
Garbe, C., Keim, U., Amaral, T. M. S., Berking, C., Eigentler, T., Flatz, L., Gesierich, A., Leiter, U., Stadler, R., Sunderkötter, C. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00202 · Cited by 120
“The rate and the type of toxicity do not differ between patients treated with adjuvant pembrolizumab in stage II and stage III.(10,14)”
BackgroundSelf-citationPre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
Lee, J., Saw, R. P. M., Thompson, J. F., Lo, S., Spillane, A. J., Shannon, K. F., Stretch, J. R., Howle, J. R., Menzies, A. M., Carlino, M. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz075 · Cited by 123
Self-citationMalignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients
Wohlmuth, C., Wieser, I., May, T., Vicus, D., Gien, L. T., & Laframboise, S. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00487-x · Cited by 119
Evolving impact of long-term survival results on metastatic melanoma treatment
Michielin, O. A., Atkins, M. B., Koon, H. B., Dummer, R., & Ascierto, P. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000948 · Cited by 125
Self-citationJohnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Immune checkpoint inhibitor-related hepatotoxicity: A review
Remash, D., Prince, D. S., McKenzie, C. A., Strasser, S. I., Kao, S., & Liu, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5376 · Cited by 133
Livingstone, E., Zimmer, L., Hassel, J. C., Fluck, M., Eigentler, T., Loquai, C., Haferkamp, S., Gutzmer, R., Meier, F. E., Mohr, P., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01654-3 · Cited by 127
Self-citationPreexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. D. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7310 · Cited by 122
Michielin, O. A., van Akkooi, A. C. J., Lorigan, P. C., Ascierto, P. A., Dummer, R., Robert, C., Arance, A. M., Blank, C. U., Chiarion‐Sileni, V., Donia, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.005 · Cited by 130
Self-citationThe Treatment of Advanced Melanoma: Therapeutic Update
Villani, A., Potestio, L., Fabbrocini, G., Troncone, G., Malapelle, U., & Scalvenzi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126388 · Cited by 138
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 148
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Grossmann, K. F., Othus, M., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., Petrella, T. M., Truong, T.-G., Khushalani, N. I., Cohen, J. V., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1141 · Cited by 111
Self-citationNext-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 126
The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy
Zhang, S., Chen, W., Zhou, J., Liang, Q., Zhang, Y., Su, M., Zhang, Z., & Qu, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s499403 · Cited by 128
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆
Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V. G., Zaman, F. Y., Young, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.471 · Cited by 113
Self-citationTiming of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
Liu, J., O’Donnell, J. S., Yan, J., Madore, J., Allen, S., Smyth, M. J., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581530 · Cited by 113
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 117
“%) of the 509 stage 3 melanoma patients treated with pembrolizumab, but in none of those treated with placebo [39].”
BackgroundJurj, A. M., Ionescu, C., Berindan‐Neagoe, I., & Braicu, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02484-1 · Cited by 116
Melanoma pathology reporting and staging
Scolyer, R. A., Rawson, R. V., Gershenwald, J. E., Ferguson, P. M., & Prieto, V. G. (2019) · Modern Pathology · doi:10.1038/s41379-019-0402-x · Cited by 111
Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options
Kohoutová, D., Worku, D. A., Aziz, H., TEARE, J. P., Weir, J., & Larkin, J. (2021) · Cells · doi:10.3390/cells10020327 · Cited by 111
“to a significantly longer recurrence-free survival compared to a placebo [60].”
BackgroundSelf-citationMiksch, R. C., Schoenberg, M. B., Weniger, M., Bösch, F., Ormanns, S., Mayer, B., Werner, J., Bazhin, A. V., & D’Haese, J. G. (2019) · Cancers · doi:10.3390/cancers11010039 · Cited by 115
Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy
Brown, Z. J., Greten, T. F., & Heinrich, B. (2019) · Hepatology · doi:10.1002/hep.30633 · Cited by 114
“(2) Recently, patients with resected stage 3 melanoma demonstrated an improved RFS with the immune checkpoint inhibitor pembrolizumab in the adjuvant setting.(3) This finding gives hope for the prospect of immunotherapy in other diseases including HCC.”
BackgroundLin, Z., Huang, L., Li, S., Gu, J., Cui, X., & Zhou, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-78560-3 · Cited by 119
Immunotherapy for Non-melanoma Skin Cancer
Shalhout, S. Z., Emerick, K. S., Kaufman, H. L., & Miller, D. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01120-z · Cited by 108
Cutaneous melanoma and the immunotherapy revolution (Review)
Leonardi, G. C., Candido, S., Falzone, L., Spandidos, D. A., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5088 · Cited by 123
“In a phase 3 double-blind trial pembrolizumab treatment resulted in significantly longer RFS than placebo with no new toxicities compared to other pembrolizumab monotherapy trials (35).”
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Basset‐Séguin, N., Bastholt, L., Bataille, V. A., Brochez, L., del Mármol, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115153 · Cited by 136
Self-citationAn open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma
Acs, B., Ahmed, F. S., Gupta, S., Wong, P. F., Gartrell, R. D., Sarin Pradhan, J., Rizk, E. M., Gould Rothberg, B., Saenger, Y. M., & Rimm, D. L. (2019) · Nature Communications · doi:10.1038/s41467-019-13043-2 · Cited by 105
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Robert, C., Marabelle, A., Herrscher, H., Caramella, C., Rouby, P., Fizazi, K. S., & Besse, B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0399-6 · Cited by 109
Self-citationHematological immune related adverse events after treatment with immune checkpoint inhibitors
Kramer, R., Zaremba, A., Moreira, A., Ugurel, S., Johnson, D. B., Hassel, J. C., Salzmann, M., Gesierich, A., Weppler, A. M., Spain, L. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.013 · Cited by 108
Self-citationNeoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
Long, G. V., Menzies, A. M., & Scolyer, R. A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02575 · Cited by 109
Self-citationZhang, N., Song, J., Liu, Y., Liu, M., Zhang, L., Sheng, D., Deng, L., Yi, H., Wu, M., Zheng, Y., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.036 · Cited by 106
Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., Meric‐Bernstam, F., Wang, Y., Levy, J., Grindheim, J. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0450 · Cited by 112
Base excision repair regulates PD-L1 expression in cancer cells
Permata, T. B. M., Hagiwara, Y., Sato, H., Yasuhara, T., Oike, T., Gondhowiardjo, S. A., Held, K. D., Nakano, T., & Shibata, A. (2019) · Oncogene · doi:10.1038/s41388-019-0733-6 · Cited by 108
Zhou, Y., Bastian, I. N., Long, M. D., Dow, M., Li, W., Liu, T., Ngu, R. K., Antonucci, L., Huang, J. Y., Phung, Q. T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025840118 · Cited by 100
“I mmune checkpoint inhibitor therapy (ICIT) had transformed cancer treatment (1 – 4), but even in ICIT-responsive metastatic melanoma and nonsmall cell lung cancer (NSCLC), response rates rarely exceed 40% (5).”
Eggermont, A. M. M., Kiciński, M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114327 · Cited by 120
Self-citationSha, C. M., Lehrer, E. J., Hwang, C., Trifiletti, D. M., Mackley, H. B., Drabick, J. J., & Zaorsky, N. G. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.07.035 · Cited by 110
“There were 35 studies with ICI alone arms totaling 13,956 patients (Supplemental Table 3).(36-71) Disease sites include cancers of head and neck, 42 stomach, 68 melanoma, 47, 50, 51, 56, 58, 59, 61, 62, 67, 70, 71 lung, 43-45, 55, 57, 60, 63, 64, 69 kidney, 53, 54, 65 prostate,(36) and urothelial origin.”
Wei, Y., Tang, X., Ren, Y., Yang, Y. S., Song, F., Fu, J., Liu, S., Yu, M., Chen, J., Wang, S., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00801-2 · Cited by 112
Williams, C. J. M., Peddle, A. M., Kasi, P. M., Seligmann, J. F., Roxburgh, C. S. D., Middleton, G., & Tejpar, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00943-6 · Cited by 110
“By contrast, evidence supports the adjuvant use of ICIs in a number of other tumour types 33–35 .”
PTEN loss correlates with T cell exclusion across human cancers
Lin, Z., Huang, L., Li, S. L., Gu, J., Cui, X., & Zhou, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08114-x · Cited by 106
Review article: new therapeutic interventions for advanced hepatocellular carcinoma
Bangaru, S. D., Marrero, J. A., & Singal, A. G. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15573 · Cited by 101
Immune checkpoint inhibitors to treat cutaneous malignancies
M.S, D. M. B., Do, M. H., Phillips, G. S., Postow, M. A., Akaike, T., Nghiem, P., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.131 · Cited by 104
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
He, Y., Wang, L., Wei, T., Xiao, Y., Sheng, H., Su, H., Hollern, D. P., Zhang, X., Ma, J., Wen, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147025 · Cited by 106
“While a significant fraction of FOXA1 mutations in cancer are C-terminal truncation mutations (29, 30), we demonstrated that different from the SBR-deficient mutant FOXA1 (1-247), the two PCa-associated C-terminal truncation mutants FOXA1 (1-290) and FOXA1 (1-268) (29, 30) remained the ability to bind to STAT2 and sup…”
BackgroundResultNanoprobe-based molecular imaging for tumor stratification
Ma, X., Mao, M., He, J., Liang, C., & Xie, H. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00063j · Cited by 99
New pathways in immune stimulation: targeting OX40
Silva, C. A. C., Facchinetti, F., Routy, B., & Derosa, L. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000573 · Cited by 97
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
Asher, N., Ben‐Betzalel, G., Ari, S. L., Shapira‐Frommer, R., Steinberg‐Silman, Y., Gochman, N., Schachter, J., Meirson, T., & Markel, G. (2020) · Cancers · doi:10.3390/cancers12082329 · Cited by 95
“In addition, PD-1 inhibitors were recently approved as an adjuvant treatment for the American Joint Committee on Cancer (AJCC) stage III melanoma, reducing the hazard ratios for disease recurrence compared to placebo [12] and to ipilimumab by half [13].”
BackgroundSystematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 98
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 91
Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019
Kahlon, N., Doddi, S., Yousif, R., Najib, S., Sheikh, T., Abuhelwa, Z., Burmeister, C., & Hamouda, D. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45269 · Cited by 100
Quek, C. Y. J., Pratapa, A., Bai, X., Al‐Eryani, G., da Silva, I. P., Mayer, A. T., Bartoniček, N., Harvey, K., Maher, N. G., Conway, J. W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114392 · Cited by 107
Self-citationImmune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
Psimaras, D., Velasco, R., Birzu, C., Tamburin, S., Lustberg, M. B., Bruna, J., & Argyriou, A. A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12339 · Cited by 102
Al-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16324 · Cited by 87
Lévesque, S., Le Naour, J., Pietrocola, F., Paillet, J., Kremer, M., Castoldi, F., Baracco, E. E., Wang, Y., Vacchelli, E., Stoll, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657375 · Cited by 86
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
Liang, Y., Liu, X., Shen, L., Hu, G., Zou, G., Zhang, N., Chen, C., Chen, X., Zhu, X., Yuan, Y., et al. (2025) · JAMA · doi:10.1001/jama.2025.1132 · Cited by 87
Self-citationEggermont, A. M. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.020 · Cited by 91
Self-citationUltrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Dinnes, J., di Ruffano, L. F., Takwoingi, Y., Cheung, S. T., Nathan, P., Matin, R., Chuchu, N., Chan, S. A., Durack, A., Bayliss, S. E., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012806.pub2 · Cited by 106
Correlation between patients' age and cancer immunotherapy efficacy.
Wu, Q., Wang, Q., Tang, X., Xu, R., Zhang, L., Chen, X., Xue, Q., Wang, Z., Shi, R., Wang, F., et al. (2019) · Europe PMC (PubMed Central) · doi:10.1080/2162402x.2019.1568810 · Cited by 103
Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 77
Metadata
- Authors
- Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C.
- Affiliations
- Aix-Marseille Université (FR)
- From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical...
- The University of Sydney (AU)
- The University of Queensland (AU)
- Edith Cowan University (AU)
- Washington University in St. Louis (US)
- University of Siena (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Eggermont, Alexander M.M.
- Blank, Christian U.
- Long, Georgina V.
- Atkinson, Victoria
- Dalle, Stéphane
- Haydon, Andrew
- Khattak, Adnan
- Carlino, Matteo S.
- Sandhu, Shahneen
- Larkin, James
- Puig, Susana
- Ascierto, Paolo A.
- Rutkowski, Piotr
- Schadendorf, Dirk
- Koornstra, Rutger
- Hernandez-Aya, Leonel
- Maio, Michele
- Grob, Jean-Jacques
- Gutzmer, Ralf
- Jamal, Rahima
- Lorigan, Paul
- Ibrahim, Nageatte
- Marreaud, Sandrine
- Suciu, Stefan
- Robert, Caroline
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1789-1801
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2797309423
- Cited by
- 1,906
- References
- 31
- Citations by year
- 2026: 131 · 2025: 171 · 2024: 207 · 2023: 204 · 2022: 236 · 2021: 308 · 2020: 307 · 2019: 250 · 2018: 87
- FWCI
- 88.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, adjuvant therapy, stage III melanoma, PD-1 inhibitors, PD-L1 expression, recurrence-free survival, resected melanoma, immune checkpoint inhibitors, adverse events, myositis, non-relapse mortality, overall survival, progression-free survival, high-risk melanoma, tumor recurrence prevention, safety and tolerability
- MeSH terms
- Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.